Drug Profile
Etirinotecan pegol - JenKem Technology
Alternative Names: JK-1201l; PEG-irinotecan - JenKem; Pegylated irinotecan - 3SBio; Pegylated irinotecan - JenKem; SSS 22Latest Information Update: 20 Dec 2021
Price :
$50
*
At a glance
- Originator JenKem Technology
- Developer 3SBio; JenKem Technology
- Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 11 Nov 2021 Phase-I/II clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (IV) (NCT05158491)
- 31 Mar 2021 JenKem Technology completes a phase I trial in in Solid tumours (Second-line therapy or greater) in China (NCT04366648)
- 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in China (IV, Infusion)